'Anti-antibiotic' Allows For Use Of Antibiotics Without Driv
Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...
An inexpensive, FDA-approved drug cholestyramine taken in conjunction with an antibiotic prevents the antibiotic from driving antimicrobial resistance, according to new research by scientists at Penn State and the University of Michigan.

E. faecium colonizes in the human gastrointestinal tract and spreads via fecal-oral transmission and is asymptomatic in the gut but can cause serious infections in bloodstream or the spinal cord. Daptomycin is one of the few remaining antibiotics to treat VR E. faecium infection, yet it quickly becoming resistant to daptomycin as well.

To investigate, the team inoculated mice orally with different strains of daptomycin-susceptible VR E. faecium. Beginning one day after inoculation, the researchers gave the mice daily doses of either subcutaneous daptomycin, oral daptomycin or a control mock injection for five days.

They collected fecal samples from the mice to measure the extent of VR E. faecium shedding into the environment and to determine daptomycin susceptibility of the E. faecium bacteria that were present in the feces.

The researchers found that only the highest doses of daptomycin consistently reduced fecal VR E. faecium below the level of detection, whereas lower doses resulted in VR E. faecium shedding and also observed that daptomycin-resistant bacteria were shed even when the daptomycin was administered subcutaneously.

Finally, the team investigated whether the orally administered adjuvant cholestyramine They found that it reduced fecal shedding of daptomycin-resistant VR E. faecium in daptomycin-treated mice by up to 80-fold.

Dr. T●●●●z H●●●●●●i and 5 others like this1 share